Mostrar o rexistro simple do ítem
Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program
dc.contributor.author | Bellido-Guerrero, Diego | |
dc.contributor.author | Morillas, Carlos | |
dc.contributor.author | Escalada, Javier | |
dc.contributor.author | Palomares, Rafael | |
dc.contributor.author | Gómez-Peralta, Fernando | |
dc.contributor.author | Pérez, Antonio | |
dc.date.accessioned | 2024-07-02T10:07:41Z | |
dc.date.available | 2024-07-02T10:07:41Z | |
dc.date.issued | 2019-07 | |
dc.identifier.citation | Morillas C, Escalada J, Palomares R, Bellido D, Gómez-Peralta F, Pérez A. Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. Diabetes Ther. 2019 Oct;10(5):1893-1907. doi: 10.1007/s13300-019-0671-x. Epub 2019 Jul 29. PMID: 31359366; PMCID: PMC6778580. | es_ES |
dc.identifier.uri | http://hdl.handle.net/2183/37624 | |
dc.description.abstract | [Abstract] Introduction: The aim of this Delphi study is to unveil the management of patients with type 2 diabetes (T2D) and different levels of complexity in the clinical practice in Spain. Methods: Based on the common management practices of T2D profiles reported by Spanish endocrinologists, a Delphi questionnaire of 55 statements was developed and responded to by a national panel (n = 101). Results: A consensus was reached for 30 of the 55 statements. Regarding overweight patients inadequately controlled with metformin, treatment with a sodium-glucose transport protein 2 inhibitor (SGLT2-I) is preferred over treatment with a dipeptidyl peptidase-4 inhibitor (DPP4-I). If the patient is already being treated with a DPP4-I, an SGLT2-I is added on to the treatment regimen rather than replacing the DPP4-I. Conversely, if the treatment regimen includes a sulfonylurea, it is usually replaced by other antihyperglycemic agents. Current treatment trends in uncontrolled obese patients include the addition of an SGLT2-I or a glucagon-like peptide-1 receptor agonist (GLP1-RA) to background therapy. When the glycated hemoglobin target is not reached, triple therapy with metformin + GLP1-RA + SGLT2-I is initiated. Although SGLT2-Is are the treatment of choice in patients with T2D and heart failure or uncontrolled hypertension, no consensus was reached regarding the preferential use of SGLT2-Is or GLP1-RAs in patients with established cardiovascular disease. Conclusion: Consensus has been reached for a variety of statements regarding the management of several T2D profiles. Achieving a more homogeneous management of complex patients with T2D may require further evidence and a better understanding of the key drivers for treatment choice. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.relation.uri | https://doi.org/10.1007/s13300-019-0671-x | es_ES |
dc.rights | Atribución-NoComercial 3.0 España | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.subject | Clinical practice | es_ES |
dc.subject | Complex patient | es_ES |
dc.subject | Delphi questionnaire | es_ES |
dc.subject | Endocrinology | es_ES |
dc.subject | Type 2 diabetes | es_ES |
dc.title | Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Diabetes Therapy | es_ES |
UDC.volume | 10 | es_ES |
UDC.issue | 5 | es_ES |
UDC.startPage | 1893 | es_ES |
UDC.endPage | 1907 | es_ES |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
II - Artigos [544]